Evoq Remedies Ltd Q2 FY26 – The Penny Pharma with a SEBI Show-Cause Twist and a ₹9.21 Cr Drama Dose
1. At a Glance
Evoq Remedies Ltd — the penny pharma that could’ve been a biotech blockbuster, but instead found itself starring in “The SEBI Show-Cause Chronicles: Preferential Allotment Edition.” The stock currently trades at a modest ₹4.91, down almost 42% in a year, yet somehow still hanging on like that one overconfident penny stock investor in every WhatsApp group who says, “Bas promoter buying aane do.”
Market cap? ₹12.2 crore — small enough to fit inside a pharma sales rep’s briefcase. Revenue (TTM) is ₹37.3 crore, and profit after tax stands at ₹1.76 crore. But here’s the kicker: a recent auditor note flags a SEBI probe into a ₹9.21 crore preferential issue, unconfirmed advances of ₹12.51 crore, and a GST demand of ₹6.55 crore. That’s not “other income,” that’s “other tension.”
Return on equity? 0.26%. ROCE? 0.35%. Promoter holding? Just 11.2%, down from 73.5% in 2022. At this point, even the company’s tagline should be, “Dilute karenge, par chhodenge nahi.”
So yes — Evoq Remedies is that microcap pharma trader that seems to prefer drama over dividends and probes over profits. But let’s unwrap this smallcap capsule layer by layer.
2. Introduction – The Saga of a Smallcap with Big Dreams and Bigger Clarifications
Welcome to the curious case of Evoq Remedies Ltd, where the share price is in single digits but the corporate announcements read like a Bollywood thriller.
Incorporated in 2010, Evoq is a pharmaceutical trader — not a manufacturer, not a R&D lab, just your friendly neighborhood middleman of formulations, APIs, nutraceuticals, and herbal potions. The kind that says “scientifically tested” and means “we Googled it once.”
Listed on the BSE SME platform in 2022 after a ₹9.72 crore IPO, Evoq came to the market with promises of growth. Fast forward to FY25–26, and the only thing growing consistently seems to be the list of show-cause notices.
The auditor’s note from October 2025 reads like a financial horror story:
SEBI probe on ₹9.21 crore preferential allotment.
Advances of ₹1,250.87 lakh not confirmed.
GST demand of ₹655.03 lakh.
Related loans of ₹668.86 lakh.
Meanwhile, sales have spiked from ₹0.15 crore in Mar’24 to ₹25.5 crore in Sep’25 — a 24,747% jump. That’s not growth; that’s a resurrection. Either they found the cure for laziness or someone finally remembered to invoice the stock lying in the warehouse.
Still, the company claims to market over 120 pharma products under its brand name — all third-party manufactured. Basically, they own the logos, not the labs.
3. Business Model – WTF Do They Even Do?
Evoq Remedies’ “business model” can be summarized as: Buy medicine from someone, put your label on it, and sell it to someone else. Think of it as the Flipkart of formulations, minus the logistics and customer service.
The company’s portfolio reads like a pharmacy shelf exploded — antibiotics, analgesics, anti-malarials, dermatology creams, gynecology pills, steroids, and even herbal products (because “Ayurvedic” adds 10% margin and 100% confidence).
But here’s the real game — Evoq doesn’t manufacture anything. It outsources production to third-party facilities and simply markets the finished products. So, in essence, Evoq trades marketing muscle for manufacturing sweat.
Their focus areas are “formulation trading” and “nutraceuticals,” which in desi terms translates to “hum medicines aur supplements dono bechte hain, depending on mood and margin.”
Sounds simple? It is — except when SEBI comes knocking about preferential allotments, and auditors start questioning advances worth crores.
If you’re wondering whether this is a pharma company or a financial experiment, you’re not alone.
4. Financials Overview
Source table
Metric
Latest Qtr (Sep’25)
YoY Qtr (Sep’24)
Prev Qtr (Mar’25)
YoY %
QoQ %
Revenue (₹ Cr)
25.51
0.00
11.76
—
116.9%
EBITDA (₹ Cr)
-0.95
-1.63
-0.60
—
-58.3%
PAT (₹ Cr)
0.05
-1.62
1.71
—
-97.1%
EPS (₹)
0.02
-0.65
0.69
—
-97.1%
Evoq went from loss-making zombie in FY24 to barely profitable amoeba in FY25, with profits of ₹0.05 crore this quarter.
Margins? Nonexistent. The company’s operating margin of -3.72% feels like a discount sale gone wrong. Still, PAT is positive — maybe due to a surprise “other income” of ₹1.06 crore.
Who needs EBITDA when you’ve got “miscellaneous income”?
5. Valuation Discussion – The Great Overvaluation or Hidden Gem?
